Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis
Summary
Background Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic variants. These variants proved to be classifiable by their likely biological action as erythrocytic (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits). In this study, we tested the hypotheses that, in a very large scale GWAS, we would identify more genetic variants associated with HbA1c and that HbA1c variants implicated in erythrocytic biology would affect the diagnostic accuracy of HbA1c. We therefore expanded the number of HbA1c-associated loci and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction and on prevalent diabetes screening performance. Throughout this multiancestry study, we kept a focus on interancestry differences in HbA1c genetics performance that might influence race-ancestry differences in health outcomes. Methods & findings Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic, or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multiethnic longitudinal cohorts (N = 33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR = 1.05, 95% CI 1.04–1.06, per HbA1c-raising allele, p = 3 × 10−29); whereas GS-E was not (OR = 1.00, 95% CI 0.99–1.01, p = 0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 0.66–0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38–0.97) in homozygous women. The G6PD variant may cause approximately 2% (N = 0.65 million, 95% CI 0.55–0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one-third of the variants. Further studies in large multiethnic cohorts with HbA1c, glycemic, and erythrocytic traits are required to better determine the biological action of the unclassified variants. Conclusions As G6PD deficiency can be clinically silent until illness strikes, we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.
Related articles
Why art? The role of arts in arts and health
This article addresses the complex relationship between the arts and health, questioning the role of the arts in improving mental and physical well-being. It explores various theoretical constructs and empirical evidence while emphasizing the need for a coherent definition of art to understand its effects on health.
Oncogenesis
This article examines the role of p52-ZER6 in the metabolic reprogramming of tumor cells, highlighting its impact on the pentose phosphate pathway and tumor progression. The study provides insights into the biochemical processes involved and points to potential therapeutic targets for cancer treatment.
From library to landscape: integrative annotation workflows for compound libraries in drug repurposing
This article details the creation of two automated annotation workflows designed for the integration of chemical and bioactivity data from various public repositories to support drug repurposing projects.
Comprehensive Hemodialysis and Nephrology Lecture
This document is a detailed lecture series on hemodialysis and nephrology, discussing the fundamentals of dialysis, historical milestones, advanced modalities, and complications associated with the treatment, aiming to enhance understanding for medical trainees and professionals.
ShiftScan: A tool for rapid analysis of high-throughput differential scanning fluorimetry data and compound prioritization
This document presents ShiftScan, a standalone tool designed for the rapid analysis of differential scanning fluorimetry (DSF) data in drug discovery, enabling efficient filtering and prioritization of compounds based on thermal transition patterns. It aims to assist researchers in managing large datasets and improving the identification of potential drug candidates.